The study demonstrates that the peptide PHDP5, which inhibits dynamin-MT interaction, can rescue impaired endocytosis and synaptic transmission caused by tau in presynaptic terminals. When administered intranasally to Alzheimer's disease (AD) model mice, PHDP5 significantly improved learning and memory, suggesting its potential as a candidate for human AD therapy.